Dr. Jiayu Wang 王佳玉
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment of soft tissue sarcomas and common medical oncology tumors. Chemotherapy, endocrine therapy, and targeted therapy for breast cancer.
Dr. Wang holds a doctorate in oncology from Peking Union Medical College and graduated from China Medical University in 1996. With 16 years in medical oncology, Dr. Wang has conducted research on breast cancer therapies. Dr. Wang participated in five national and provincial research projects and multiple international multicenter clinical trials, publishing over 30 papers and co-authoring two academic monographs.
Name order: in Chinese the family name comes first (Wang Jiayu). Papers usually list the name as Jiayu Wang or Wang J.
Selected publications
166 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- N Engl J Med, 2026 (first author): Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer. PubMed 42929681
- JAMA Oncol, 2026 (first author): Interpretation of the BRIGHT-2 Trial-Reply. PubMed 42530950
- Nat Commun, 2026 (first author): Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial. PubMed 42802176
- JAMA Oncol, 2026 (first author): Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. PubMed 41854603
- Ther Adv Med Oncol, 2025 (senior author): Efficacy and safety of vascular-targeting agents in advanced soft tissue sarcoma: a systematic review and network meta-analysis. PubMed 41132824
- BMC Med, 2025 (first author): Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial. PubMed 41063198
- Cancer Commun (Lond), 2025 (first author): An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial. PubMed 40013319
- Nat Commun, 2025 (first author): Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis. PubMed 40204778
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion